Provided by Tiger Fintech (Singapore) Pte. Ltd.

Blueprint Medicines

89.58
-0.2600-0.29%
Post-market: 89.580.00000.00%16:23 EDT
Volume:669.70K
Turnover:59.83M
Market Cap:5.72B
PE:-83.93
High:90.84
Open:90.44
Low:88.00
Close:89.84
Loading ...

Blueprint Medicines Forecasts 2025 Global Ayvakit Net Product Revenues Of Approximately $680M-$710M

Benzinga
·
13 Feb

Blueprint Medicines Q4 2024 GAAP EPS $(0.79) Misses $(0.70) Estimate, Sales $146.37M Beat $145.84M Estimate

Benzinga
·
13 Feb

Blueprint Medicines Corp: Anticipate Global Ayvakit Net Product Revenue of Approximately $680 Mln to $710 Mln in 2025

THOMSON REUTERS
·
13 Feb

Blueprint Medicines - Updates Systemic Mastocytosis Franchise Revenue Opportunity to $4 Billion by 2030

THOMSON REUTERS
·
13 Feb

Blueprint Medicines Corp: Expects Further Cash Burn Reduction in 2025

THOMSON REUTERS
·
13 Feb

Blueprint Medicines Corp: Anticipate Global Ayvakit Net Product Revenue of About $680 Mln to $710 Mln in 2025

THOMSON REUTERS
·
13 Feb

BRIEF-Blueprint Medicines Q4 Net Income USD -49.956 Million Vs. IBES Estimate USD -44.7 Million

Reuters
·
13 Feb

Blueprint Medicines Q4 Net Income USD -49.956 Million VS. Ibes Estimate USD -44.7 Million

THOMSON REUTERS
·
13 Feb

Earnings Preview: Axsome Therapeutics (AXSM) Q4 Earnings Expected to Decline

Zacks
·
11 Feb

Barclays Keeps Their Hold Rating on Blueprint Medicines (BPMC)

TIPRANKS
·
11 Feb

JMP Securities Reaffirms Their Buy Rating on Blueprint Medicines (BPMC)

TIPRANKS
·
07 Feb

Will Blueprint Medicines (BPMC) Report Negative Earnings Next Week? What You Should Know

Zacks
·
06 Feb

Should You Buy Blueprint Medicines (BPMC) After Golden Cross?

Zacks
·
06 Feb

Blueprint Medicines Is Maintained at Overweight by JP Morgan

Dow Jones
·
04 Feb

Blueprint Medicines Is Maintained at Neutral by Piper Sandler

Dow Jones
·
27 Jan

Blueprint Medicines price target raised to $119 from $109 at Piper Sandler

TIPRANKS
·
27 Jan